Jie Zeng Yu

Dr. Jie Zeng Yu

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JWJiexi Wen
Jiexi Wen
JYJie Zeng Yu
Jie Zeng Yu
CLCatherine Liu
Catherine Liu
AIAbdol Aziz Ould Ismail
Abdol Aziz Ould Ismail
Weijie MaWeijie Ma
Weijie Ma
Brain metastases represent a significant clinical challenge in the treatment of non-small-cell lung cancer (NSCLC), often leading to a severe decline in patient prognosis and survival. Recent advances in imaging and systemic treatments have increased the detection rates of brain metastases, yet clinical outcomes remain dismal due to the complexity of the metastatic tumor microenvironment (TME) and the lack of specific biomarkers for early detection and targeted therapy. The intricate interplay between NSCLC tumor cells and the surrounding TME in brain metastases is pivotal, influencing tumor progression, immune evasion, and response to therapy. This underscores the necessity for a deeper understanding of the molecular underpinnings of brain metastases, tumor microenvironment, and the identification of actionable biomarkers that can inform multimodal treatment approaches. The goal of this review is to synthesize current insights into the TME and elucidate molecular mechanisms in NSCLC brain metastases. Furthermore, we will explore the promising horizon of emerging biomarkers, both tissue- and liquid-based, that hold the potential to radically transform the treatment strategies and the enhancement of patient outcomes.

10 March 2026 in Nature Materials
Verified
Journal Article
Open access
PDF file
AGAustin J. Graham
Austin J. Graham
MKMichelle W. L. Khoo
Michelle W. L. Khoo
VSVasudha Srivastava
Vasudha Srivastava
SVSara Viragova
Sara Viragova
HKHonesty Kim
Honesty Kim
ZGZev J. Gartner
Zev J. Gartner
Complex and robust tissue self-organization requires defined initial conditions and dynamic boundaries—neighbouring tissues and extracellular matrix that actively evolve to guide morphogenesis. A major challenge in tissue engineering is identifying material properties that are compatible with controlling initial culture conditions while mimicking dynamic tissue boundaries. Here we describe a highly tunable granular biomaterial, MAGIC matrix, that supports both long-term bioprinting and gold-standard tissue self-organization. We identify that significant stress relaxation at the long timescales and large deformation magnitudes relevant to self-organization is required for optimal morphogenesis. We apply optimized MAGIC matrices toward precise extrusion bioprinting of saturated cell suspensions directly into three-dimensional culture. Carefully controlling initial conditions for tissue growth yields dramatic increases in organoid reproducibility and complexity across multiple tissue types, enabling high-throughput generation of organoid arrays and perfusable three-dimensional microphysiological systems. Our results identify key biomaterial parameters for optimal organoid morphogenesis and lay the foundation for fabricating more complex and reproducible self-organized tissues.

15 October 2024 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
NCNam Woo Cho
Nam Woo Cho
SGSophia M. Guldberg
Sophia M. Guldberg
BNBarzin Y. Nabet
Barzin Y. Nabet
JYJie Zeng Yu
Jie Zeng Yu
EKEun Ji Kim
Eun Ji Kim
MSMatthew H. Spitzer
Matthew H. Spitzer
Resistance to immune checkpoint inhibitors (ICI) is common, even in tumors with T-cell infiltration. We thus investigated consequences of ICI-induced T-cell infiltration in the microenvironment of resistant tumors. T cells and neutrophil numbers increased in ICI-resistant tumors following treatment, in contrast to ICI-responsive tumors. Resistant tumors were distinguished by high expression of IL1 receptor 1, enabling a synergistic response to IL1 and TNFα to induce G-CSF, CXCL1, and CXCL2 via NF-κB signaling, supporting immunosuppressive neutrophil accumulation in tumor. Perturbation of this inflammatory resistance circuit sensitized tumors to ICIs. Paradoxically, T cells drove this resistance circuit via TNFα both in vitro and in vivo. Evidence of this inflammatory resistance circuit and its impact also translated to human cancers. These data support a mechanism of ICI resistance, wherein treatment-induced T-cell activity can drive resistance in tumors responsive to IL1 and TNFα, with important therapeutic implications.

18 January 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
Weijie MaWeijie Ma
Weijie Ma
SWSixi Wei
Sixi Wei
QLQianping Li
Qianping Li
JYJie Zeng Yu
Jie Zeng Yu
WXWenwu Xiao
Wenwu Xiao
TLTianhong Li
Tianhong Li
There is an unmet clinical need to develop novel strategies to overcome resistance to tyrosine kinase inhibitors (TKI) in patients with oncogene-driven lung adenocarcinoma (LUAD). The objective of this study was to determine whether simvastatin could overcome TKI resistance using the in vitro and in vivo LUAD models. Human LUAD cell lines, tumor cells, and patient-derived xenograft (PDX) models from TKI-resistant LUAD were treated with simvastatin, either alone or in combination with a matched TKI. Tumor growth inhibition was measured by the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay and expression of molecular targets was assessed by immunoblots. Tumors were assessed by histopathology, IHC stain, immunoblots, and RNA sequencing. We found that simvastatin had a potent antitumor effect in tested LUAD cell lines and PDX tumors, regardless of tumor genotypes. Simvastatin and TKI combination did not have antagonistic cytotoxicity in these LUAD models. In an osimertinib-resistant LUAD PDX model, simvastatin and osimertinib combination resulted in a greater reduction in tumor volume than simvastatin alone (P < 0.001). Immunoblots and IHC stain also confirmed that simvastatin inhibited TKI targets. In addition to inhibiting 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase, RNA sequencing and Western blots identified the proliferation, migration, and invasion-related genes (such as PI3K/Akt/mTOR, YAP/TAZ, focal adhesion, extracellular matrix receptor), proteasome-related genes, and integrin (α3β1, αvβ3) signaling pathways as the significantly downregulated targets in these PDX tumors treated with simvastatin and a TKI. The addition of simvastatin is a safe approach to overcome acquired resistance to TKIs in several oncogene-driven LUAD models, which deserve further investigation.

25 December 2024 in Cancers
Verified
Journal Article
Open access
PDF file
JYJie Zeng Yu
Jie Zeng Yu
ZKZsofia Kiss
Zsofia Kiss
Weijie MaWeijie Ma
Weijie Ma
RLRuqiang Liang
Ruqiang Liang
TLTianhong Li
Tianhong Li
Patient-centered precision oncology strives to deliver individualized cancer care. In lung cancer, preclinical models and technological innovations have become critical in advancing this approach. Preclinical models enable deeper insights into tumor biology and enhance the selection of appropriate systemic therapies across chemotherapy, targeted therapies, immunotherapies, antibody–drug conjugates, and emerging investigational treatments. While traditional human lung cancer cell lines offer a basic framework for cancer research, they often lack the tumor heterogeneity and intricate tumor–stromal interactions necessary to accurately predict patient-specific clinical outcomes. Patient-derived xenografts (PDXs), however, retain the original tumor’s histopathology and genetic features, providing a more reliable model for predicting responses to systemic therapeutics, especially molecularly targeted therapies. For studying immunotherapies and antibody–drug conjugates, humanized PDX mouse models, syngeneic mouse models, and genetically engineered mouse models (GEMMs) are increasingly utilized. Despite their value, these in vivo models are costly, labor-intensive, and time-consuming. Recently, patient-derived lung cancer organoids (LCOs) have emerged as a promising in vitro tool for functional precision oncology studies. These LCOs demonstrate high success rates in growth and maintenance, accurately represent the histology and genomics of the original tumors and exhibit strong correlations with clinical treatment responses. Further supported by advancements in imaging, spatial and single-cell transcriptomics, proteomics, and artificial intelligence, these preclinical models are reshaping the landscape of drug development and functional precision lung cancer research. This integrated approach holds the potential to deliver increasingly accurate, personalized treatment strategies, ultimately enhancing patient outcomes in lung cancer.

3 February 2025
Verified
Other
Open access
NCNam Woo Cho
Nam Woo Cho
SGSophia M. Guldberg
Sophia M. Guldberg
BNBarzin Y. Nabet
Barzin Y. Nabet
JYJie Zeng Yu
Jie Zeng Yu
EKEun Ji Kim
Eun Ji Kim
MSMatthew H. Spitzer
Matthew H. Spitzer
Resistance to immune checkpoint inhibitors (ICI) is common, even in tumors with T-cell infiltration. We thus investigated consequences of ICI-induced T-cell infiltration in the microenvironment of resistant tumors. T cells and neutrophil numbers increased in ICI-resistant tumors following treatment, in contrast to ICI-responsive tumors. Resistant tumors were distinguished by high expression of IL1 receptor 1, enabling a synergistic response to IL1 and TNFα to induce G-CSF, CXCL1, and CXCL2 via NF-κB signaling, supporting immunosuppressive neutrophil accumulation in tumor. Perturbation of this inflammatory resistance circuit sensitized tumors to ICIs. Paradoxically, T cells drove this resistance circuit via TNFα both in vitro and in vivo. Evidence of this inflammatory resistance circuit and its impact also translated to human cancers. These data support a mechanism of ICI resistance, wherein treatment-induced T-cell activity can drive resistance in tumors responsive to IL1 and TNFα, with important therapeutic implications.